JP2023514324A5 - - Google Patents
Info
- Publication number
- JP2023514324A5 JP2023514324A5 JP2022549457A JP2022549457A JP2023514324A5 JP 2023514324 A5 JP2023514324 A5 JP 2023514324A5 JP 2022549457 A JP2022549457 A JP 2022549457A JP 2022549457 A JP2022549457 A JP 2022549457A JP 2023514324 A5 JP2023514324 A5 JP 2023514324A5
- Authority
- JP
- Japan
- Prior art keywords
- nanocarrier
- prodrug
- lipid
- item
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025204012A JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062995887P | 2020-02-19 | 2020-02-19 | |
| US62/995,887 | 2020-02-19 | ||
| PCT/US2021/010005 WO2021167703A1 (en) | 2020-02-19 | 2021-02-19 | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204012A Division JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514324A JP2023514324A (ja) | 2023-04-05 |
| JP2023514324A5 true JP2023514324A5 (https=) | 2024-02-27 |
| JP7842690B2 JP7842690B2 (ja) | 2026-04-08 |
Family
ID=75223393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549457A Active JP7842690B2 (ja) | 2020-02-19 | 2021-02-19 | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
| JP2025204012A Pending JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204012A Pending JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なＴＦＧβアンタゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11801304B2 (https=) |
| EP (1) | EP4096716A1 (https=) |
| JP (2) | JP7842690B2 (https=) |
| KR (2) | KR20220143063A (https=) |
| CN (3) | CN115243724B (https=) |
| AU (2) | AU2021223336A1 (https=) |
| CA (1) | CA3170142A1 (https=) |
| WO (1) | WO2021167703A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021167703A1 (en) * | 2020-02-19 | 2021-08-26 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
| CN112669958B (zh) * | 2020-12-08 | 2022-09-09 | 河北医科大学第二医院 | 代谢物作为疾病诊断的生物标志物 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539748A1 (en) * | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| WO2006031471A2 (en) | 2004-09-01 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Liposomal vectors |
| US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| EP1966243B1 (en) | 2005-12-23 | 2012-02-15 | Eli Lilly And Company | Tgf-beta binding antibodies |
| MX2010010165A (es) | 2008-03-17 | 2010-11-25 | Scripps Research Inst | Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas. |
| PT104158B (pt) | 2008-08-18 | 2011-02-24 | Univ Do Minho | Aplicação da monooleína como novo lípido adjuvante em lipofecção |
| CA2777720C (en) | 2009-10-16 | 2020-10-06 | The Scripps Research Institute | Induction of pluripotent cells |
| US20130189780A1 (en) | 2009-12-31 | 2013-07-25 | Fate Therapeutics, Inc. | Reprogramming compositions |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US8871744B2 (en) * | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| CN103732623B (zh) | 2011-06-03 | 2017-09-29 | 佐马技术有限公司 | 对TGF‑β具有特异性的抗体 |
| JP6076968B2 (ja) | 2011-06-06 | 2017-02-08 | ユニバーシティ・ヘルス・ネットワーク | ポルフィリン−リン脂質コンジュゲートを合成する方法 |
| AU2012308302A1 (en) | 2011-09-14 | 2014-03-20 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
| WO2013078286A1 (en) | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
| US8871189B2 (en) * | 2011-11-30 | 2014-10-28 | Mallinckrodt Llc | MMP-targeted therapeutic and/or diagnostic nanocarriers |
| EP2852380A4 (en) * | 2012-05-23 | 2016-01-20 | Univ Ohio State | LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| CN120796168A (zh) | 2013-06-11 | 2025-10-17 | 哈佛学院校长同事会 | SC-β细胞以及用于产生其的组合物和方法 |
| US10239903B2 (en) | 2014-05-02 | 2019-03-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pt (IV) derivatives and nanocarriers comprising them |
| EP3189134A1 (en) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| WO2016149756A1 (en) | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| WO2016158809A1 (ja) * | 2015-03-27 | 2016-10-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| SG11201805186VA (en) | 2016-01-20 | 2018-07-30 | Fate Therapeutics Inc | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN106176609B (zh) * | 2016-08-22 | 2019-10-15 | 南通大学 | 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用 |
| EP3532103B1 (en) * | 2016-10-26 | 2025-12-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| AU2018228435C1 (en) | 2017-03-02 | 2025-09-18 | National Research Council Of Canada | TGF-beta-receptor ectodomain fusion molecules and uses thereof |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| CA3063932A1 (en) | 2017-05-18 | 2018-11-12 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| US11433143B2 (en) | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| WO2019084455A1 (en) | 2017-10-26 | 2019-05-02 | Southern Research Institute | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS |
| WO2020013803A1 (en) | 2018-07-09 | 2020-01-16 | Synthis, Llc | Antibody-alk5 inhibitor conjugates and their uses |
| WO2020257635A1 (en) * | 2019-06-21 | 2020-12-24 | The University Of North Carolina At Chapel Hill | Drug delivery compositions and applications thereof |
| WO2021167703A1 (en) * | 2020-02-19 | 2021-08-26 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
-
2021
- 2021-02-19 WO PCT/US2021/010005 patent/WO2021167703A1/en not_active Ceased
- 2021-02-19 KR KR1020227031715A patent/KR20220143063A/ko active Pending
- 2021-02-19 CA CA3170142A patent/CA3170142A1/en active Pending
- 2021-02-19 JP JP2022549457A patent/JP7842690B2/ja active Active
- 2021-02-19 US US17/300,063 patent/US11801304B2/en active Active
- 2021-02-19 CN CN202180019109.8A patent/CN115243724B/zh active Active
- 2021-02-19 EP EP21714458.3A patent/EP4096716A1/en active Pending
- 2021-02-19 AU AU2021223336A patent/AU2021223336A1/en active Pending
- 2021-02-19 CN CN202511406387.5A patent/CN121287708A/zh active Pending
-
2023
- 2023-07-10 US US18/445,323 patent/US20240050575A1/en active Pending
-
2024
- 2024-05-13 KR KR1020267003654A patent/KR20260035240A/ko active Pending
- 2024-05-13 CN CN202480045094.6A patent/CN121487753A/zh active Pending
- 2024-05-13 US US18/831,041 patent/US20250032620A1/en active Pending
- 2024-05-13 AU AU2024339588A patent/AU2024339588A1/en active Pending
-
2025
- 2025-11-26 JP JP2025204012A patent/JP2026032152A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113645960B (zh) | 含有氧化的胆固醇的药物递送系统 | |
| US20250195641A1 (en) | Immunotherapeutic constructs and methods of their use | |
| US12059500B2 (en) | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | |
| JP6427097B2 (ja) | 癌を処置するための組成物および該組成物を製造するための方法 | |
| CN116133652A (zh) | 制备脂质纳米粒子的方法 | |
| JP7566629B2 (ja) | ランゲリン＋細胞ターゲティング | |
| JP2023514324A5 (https=) | ||
| JP2024515650A5 (https=) | ||
| US11110168B2 (en) | Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent | |
| JP7561146B2 (ja) | 接着している粒子を有する赤血球に関連する組成物および方法 | |
| Szebeni et al. | Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes | |
| US20190298824A1 (en) | Albumin-binding immunomodulatory compositions and methods of use thereof | |
| US20210177871A1 (en) | Methods for cancer therapy | |
| US20210128725A1 (en) | Cytotoxic lipid particles targeted to tumor-associated myeloid cells (tamcs) and synergized with radiation therapy for treating glioblastoma | |
| KR20230004563A (ko) | 강력한 암 면역치료제로서 리포좀성 구형 핵산 내 캡슐화된 산화된 종양 세포 용해물 | |
| CN118215496A (zh) | 抗原和药物-脂质缀合物的免疫调节组合 | |
| EP4622631A1 (en) | Compositions and methods of use thereof for increasing immune responses | |
| US20240376479A1 (en) | Aptamers for targeted activation of t cell-mediated immunity | |
| WO2018084168A1 (ja) | 皮膚線維症処置剤 | |
| US20240417738A1 (en) | Immunotherapies for the treatment of cancer | |
| US20230102840A1 (en) | Compositions and methods relating to combinatorial hyaluronic acid conjugates | |
| US20260124210A1 (en) | Therapeutic constructs for co-delivery of anti-cancer agent(s) and immune checkpoint inhibitor(s) | |
| CA3178156A1 (en) | Ethanolamine formulation for treating epithelial ovarian carcinoma | |
| Silva | Combinatorial prospects of nanoparticle mediated immunotherapy of cancer |